The National Cancer Institute has made clinical trial participation a top national priority and yet participant levels are still not perhaps where they could be. Yes, this is a big decision for any patient/physician to make as far as whether or not to enroll, but many trials are offering lifesaving...
Posted to
The Medical Quack .... by Barbara Duck
on 11-02-2008
Filed under: Medically Related, Pharma/FDA News, My Commentaries, Investors, health insurance, Pharma, Cancer, clinical trials, HMO, Pharmaceuticals, R and D, Drug Development, Cancer Institute
This interview from Charlie Roses touches on many items and Nobel Prize Winner Muhammad Yunus adds what he has been able to accomplish in his part of the world in Bangladesh and how some of those principles can be applied here, coming together of both sides, different minds, different ideas that can...
Posted to
The Medical Quack .... by Barbara Duck
on 10-28-2008
Filed under: Medically Related, Insurance, Other Items of Interest, My Commentaries, healthcare, Biotech, Cancer, Pharmaceuticals, R and D, Economy, Banking, Milken Institute, Mahammed Yunus, Milken, Charlie Rose
It should be the discretion of individual physicians, not insurance companies or pharmacies, to substitute a branded biologic for a biosimilar, which goes back to putting the physician in the decision making process, not the non clinical analyzers. While the search for "cheap" continues...
Posted to
The Medical Quack .... by Barbara Duck
on 08-14-2008
Filed under: Medically Related, Technology, My Commentaries, DNA, Genomics, Biotech, Research, Congress, Pharmaceuticals, Biosimilars